TH-302; Evofosfamide
Lintlha tsa Sehlahisoa
Li-tag tsa Sehlahisoa
| Boholo ba Pakete | Ho fumaneha | Theko (USD) |
| 100mg | E teng thepeng e teng ka lebenkeleng | 360 |
| 1g | E teng thepeng e teng ka lebenkeleng | 1000 |
| Boholo bo Eketsehileng | Fumana Litlhaloso | Fumana Litlhaloso |
Lebitso la lik'hemik'hale:
N,N'-Bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester
SMILES Khouto:
O=P(NCCBr)(NCCBr)OCC1=CN=C([N+]([O-])=O)N1C
Khoutu ea InChi:
InChI=1S/C9H16Br2N5O4P/c1-15-8(6-12-9(15)16(17)18)7-20-21(19,13-4-2-10)14-5-3-11/ h6H,2-5,7H2,1H3,(H2,13,14,19)
InChi Key:
UGJWRPJDTDGERK-UHFFFAOYSA-N
Keyword:
TH-302, TH302, TH 302, Evofosfamide, 918633-87-1
Sollubility:E qhibiliha ka DMSO
Polokelo:0 - 4 ° C bakeng sa nako e khutšoanyane (matsatsi ho isa libeke), kapa -20 ° C bakeng sa nako e telele (likhoeli)
Tlhaloso:
Evofosfamide, eo hape e tsejoang ka hore ke TH-302, ke sehlahisoa sa hypoxia-activated se nang le 2-nitroimidazole phosphoramidate conjugate e nang le ts'ebetso e ka bang teng ea antineoplastic. Karolo ea 2-nitroimidazole ea hypoxia-activated prodrug TH-302 e sebetsa e le hypoxic trigger, e lokollang DNA-alkylating dibromo isophosphoramide mustard moiety ka har'a libaka tsa hypoxic tsa lihlahala. Li-tissue tsa Normoxic li ka bolokeha ka lebaka la ts'ebetso e khethehileng ea hypoxia ea moemeli enoa, e ka fokotsang chefo ea tsamaiso. Sheba liteko tse sebetsang tsa tleliniki kapa liteko tse koetsoeng tsa bongaka u sebelisa moemeli enoa. (NCI).
Sepheo: DNA Alkylating Agent
